Armistice Capital Master Fund Ltd. - Net Worth and Insider Trading

Armistice Capital Master Fund Ltd. Net Worth

The estimated net worth of Armistice Capital Master Fund Ltd. is at least $246 Million dollars as of 2024-04-30. Armistice Capital Master Fund Ltd. is the 10% Owner of Del Frisco′s Restaurant Group Inc and owns about 12,650,000 shares of Del Frisco′s Restaurant Group Inc (DFRG) stock worth over $101 Million. Armistice Capital Master Fund Ltd. is the 10% Owner of AMAG Pharmaceuticals Inc and owns about 4,468,000 shares of AMAG Pharmaceuticals Inc (AMAG) stock worth over $61 Million. Armistice Capital Master Fund Ltd. is also the 10% Owner of Cassava Sciences Inc and owns about 1,651,340 shares of Cassava Sciences Inc (SAVA) stock worth over $37 Million. Besides these, Armistice Capital Master Fund Ltd. also holds Reshape Lifesciences Inc (RSLS) , Innovus Pharmaceuticals Inc (INNV) , Alimera Sciences Inc (ALIM) , Cyclo Therapeutics Inc (CYTH) , Aytu BioPharma Inc (AYTU) , Achieve Life Sciences Inc (ACHV) , Vaxart Inc (VXRT) , Traws Pharma Inc (TRAW) , Avalo Therapeutics Inc (AVTX) , Bio-Path Holdings Inc (BPTH) , Fresh Tracks Therapeutics Inc (FRTX) , Kiora Pharmaceuticals Inc (KPRX) , Tenax Therapeutics Inc (TENX) , Valeritas Holdings Inc (VLRXQ) . Details can be seen in Armistice Capital Master Fund Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Armistice Capital Master Fund Ltd. has not made any transactions after 2023-06-27 and currently still holds the listed stock(s).

Transaction Summary of Armistice Capital Master Fund Ltd.

To

Armistice Capital Master Fund Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Armistice Capital Master Fund Ltd. owns 20 companies in total, including Cyclo Therapeutics Inc (CYTH) , Reshape Lifesciences Inc (RSLS) , and Tenax Therapeutics Inc (TENX) among others .

Click here to see the complete history of Armistice Capital Master Fund Ltd.’s form 4 insider trades.

Insider Ownership Summary of Armistice Capital Master Fund Ltd.

Ticker Comapny Transaction Date Type of Owner
CYTH Cyclo Therapeutics Inc 2020-09-30 10 percent owner
RSLS Reshape Lifesciences Inc 2020-12-04 10 percent owner
TENX Tenax Therapeutics Inc 2021-07-08 director
AVTX Avalo Therapeutics Inc 2023-06-27 director & 10 percent owner
TTPH Tetraphase Pharmaceuticals Inc 2020-07-28 director & 10 percent owner
VXRT Vaxart Inc 2020-06-29 10 percent owner
AYTU Aytu BioPharma Inc 2020-12-11 10 percent owner
AMAG AMAG Pharmaceuticals Inc 2020-03-16 10 percent owner
INNV Innovus Pharmaceuticals Inc 2020-02-14 10 percent owner
KPRX Kiora Pharmaceuticals Inc 2021-08-02 director & 10 percent owner
VLRXQ Valeritas Holdings Inc 2019-12-20 10 percent owner
DFRG Del Frisco′s Restaurant Group Inc 2019-09-25 10 percent owner
TRAW Traws Pharma Inc 2019-09-23 10 percent owner
ACHV Achieve Life Sciences Inc 2019-06-11 10 percent owner
BPTH Bio-Path Holdings Inc 2019-01-18 10 percent owner
FRTX Fresh Tracks Therapeutics Inc 2019-01-10 10 percent owner
SAVA Cassava Sciences Inc 2018-10-03 10 percent owner
SEEL Seelos Therapeutics Inc 2018-09-20 10 percent owner
ALIM Alimera Sciences Inc 2018-02-06 10 percent owner
DYNT Dynatronics Corp 2017-03-21 10 percent owner

Armistice Capital Master Fund Ltd. Latest Holdings Summary

Armistice Capital Master Fund Ltd. currently owns a total of 17 stocks. Among these stocks, Armistice Capital Master Fund Ltd. owns 12,650,000 shares of Del Frisco′s Restaurant Group Inc (DFRG) as of June 4, 2019, with a value of $101 Million and a weighting of 41.02%. Armistice Capital Master Fund Ltd. owns 4,468,000 shares of AMAG Pharmaceuticals Inc (AMAG) as of March 16, 2020, with a value of $61 Million and a weighting of 24.96%. Armistice Capital Master Fund Ltd. also owns 1,651,340 shares of Cassava Sciences Inc (SAVA) as of October 3, 2018, with a value of $37 Million and a weighting of 14.96%. The other 14 stocks Reshape Lifesciences Inc (RSLS) , Innovus Pharmaceuticals Inc (INNV) , Alimera Sciences Inc (ALIM) , Cyclo Therapeutics Inc (CYTH) , Aytu BioPharma Inc (AYTU) , Achieve Life Sciences Inc (ACHV) , Vaxart Inc (VXRT) , Traws Pharma Inc (TRAW) , Avalo Therapeutics Inc (AVTX) , Bio-Path Holdings Inc (BPTH) , Fresh Tracks Therapeutics Inc (FRTX) , Kiora Pharmaceuticals Inc (KPRX) , Tenax Therapeutics Inc (TENX) , Valeritas Holdings Inc (VLRXQ) have a combined weighting of 19.06% among all his current holdings.

Latest Holdings of Armistice Capital Master Fund Ltd.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
DFRG Del Frisco′s Restaurant Group Inc 2019-06-04 12,650,000 7.98 100,947,000
AMAG AMAG Pharmaceuticals Inc 2020-03-16 4,468,000 13.75 61,435,000
SAVA Cassava Sciences Inc 2018-10-03 1,651,340 22.30 36,824,882
RSLS Reshape Lifesciences Inc 2020-12-04 10,660,554 2.76 29,423,129
INNV Innovus Pharmaceuticals Inc 2019-09-17 600,000 20.82 12,492,000
ALIM Alimera Sciences Inc 2018-02-06 924,805 3.67 3,394,034
CYTH Cyclo Therapeutics Inc 2020-09-30 315,915 1.47 464,395
AYTU Aytu BioPharma Inc 2020-12-11 133,333 2.81 374,666
ACHV Achieve Life Sciences Inc 2019-06-11 79,659 4.57 364,042
VXRT Vaxart Inc 2020-06-29 291,046 0.71 207,603
TRAW Traws Pharma Inc 2019-09-23 108,894 0.64 69,692
AVTX Avalo Therapeutics Inc 2023-06-27 3,191 16.88 53,864
BPTH Bio-Path Holdings Inc 2019-01-18 12,930 2.85 36,851
FRTX Fresh Tracks Therapeutics Inc 2019-01-10 13,778 0.91 12,541
KPRX Kiora Pharmaceuticals Inc 2021-08-02 19,625 0.48 9,461
TENX Tenax Therapeutics Inc 2020-09-08 2,525 3.67 9,267
VLRXQ Valeritas Holdings Inc 2019-12-20 0 0.02 0

Holding Weightings of Armistice Capital Master Fund Ltd.


Armistice Capital Master Fund Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Armistice Capital Master Fund Ltd. has made a total of 4 transactions in Del Frisco′s Restaurant Group Inc (DFRG) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Del Frisco′s Restaurant Group Inc is the acquisition of 25,000 shares on June 4, 2019, which cost Armistice Capital Master Fund Ltd. around $149,000.

According to the SEC Form 4 filings, Armistice Capital Master Fund Ltd. has made a total of 7 transactions in AMAG Pharmaceuticals Inc (AMAG) over the past 5 years, including 6 buys and 1 sells. The most-recent trade in AMAG Pharmaceuticals Inc is the acquisition of 24,000 shares on March 16, 2020, which cost Armistice Capital Master Fund Ltd. around $116,880.

According to the SEC Form 4 filings, Armistice Capital Master Fund Ltd. has made a total of 0 transactions in Cassava Sciences Inc (SAVA) over the past 5 years. The most-recent trade in Cassava Sciences Inc is the sale of 512,660 shares on October 3, 2018, which brought Armistice Capital Master Fund Ltd. around $671,585.

More details on Armistice Capital Master Fund Ltd.'s insider transactions can be found in the Insider Trading History of Armistice Capital Master Fund Ltd. table.

Insider Trading History of Armistice Capital Master Fund Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Armistice Capital Master Fund Ltd. Trading Performance

GuruFocus tracks the stock performance after each of Armistice Capital Master Fund Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Armistice Capital Master Fund Ltd. is 19.97%. GuruFocus also compares Armistice Capital Master Fund Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Armistice Capital Master Fund Ltd. within 3 months outperforms 80 times out of 159 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Armistice Capital Master Fund Ltd.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Armistice Capital Master Fund Ltd.

Average Return

83.83%

Average return per transaction

Outperforming Transactions

34%

44 out of 129 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 4.1 19.97 42.74 83.83 -1.17 -22.98
Relative Return to S&P 500(%) 2.53 16.12 36.69 70.47 -13.18 -36.52

Armistice Capital Master Fund Ltd. Ownership Network

Ownership Network List of Armistice Capital Master Fund Ltd.

No Data

Ownership Network Relation of Armistice Capital Master Fund Ltd.


Armistice Capital Master Fund Ltd. Owned Company Details

What does Cyclo Therapeutics Inc do?

Who are the key executives at Cyclo Therapeutics Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Cyclo Therapeutics Inc. Other key executives at Cyclo Therapeutics Inc include 10 percent owner Rafael Holdings, Inc. , director & Chief Executive Officer Jeffrey Tate , and SVP for Medical Affairs Sharon Hemond Hrynkow .

Cyclo Therapeutics Inc (CYTH) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Cyclo Therapeutics Inc (CYTH). Other recent insider transactions involving Cyclo Therapeutics Inc (CYTH) include a net purchase of 4,000,000 shares made by Rafael Holdings, Inc. , a net purchase of 299,402 shares made by N Scott Fine , and a net purchase of 59,881 shares made by Francis Patrick Ostronic .

In summary, during the past 3 months, insiders sold 0 shares of Cyclo Therapeutics Inc (CYTH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclo Therapeutics Inc (CYTH) were sold and 4,449,105 shares were bought by its insiders, resulting in a net purchase of 4,449,105 shares.

Cyclo Therapeutics Inc (CYTH)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cyclo Therapeutics Inc Insider Transactions

No Available Data

Armistice Capital Master Fund Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Armistice Capital Master Fund Ltd.. You might contact Armistice Capital Master Fund Ltd. via mailing address: C/o Armistice Capital, Llc, 510 Madison Avenue, 7th Floor, New York Ny 10022.

Discussions on Armistice Capital Master Fund Ltd.

No discussions yet.